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Summary
Recent studies have demonstrated that the improved pro-
gnosis derived from resection of gliomas largely depends
on the extent and quality of the resection, making max-
imum but safe resection the ultimate goal. Simultaneously,
technical innovations and refined neurosurgical methods
have rapidly improved efficacy and safety. Because glio-
mas derive from intrinsic brain cells, they often cannot
be visually distinguished from the surrounding brain tissue
during surgery. In order to appreciate the full extent of their
solid compartment, various technologies have recently
been introduced. However, radical resection of infiltrative
glioma puts neurological function at risk, with potential
detrimental consequences for patients’ survival and quality
of life. The allocation of various neurological functions
within the brain varies in each patient and may undergo ad-
ditional changes in the presence of a tumour (brain plasti-
city), making intra-operative localisation of eloquent areas
mandatory for preservation of essential brain functions.
Combining methods that visually distinguish tumour tissue
and detect tissues responsible for critical functions now
enables resection of tumours in brain regions that were
previously considered off-limits, and benefits patients by
enabling a more radical resection, while simultaneously
lowering the risk of neurological deficits. Here we review
recent and expected developments in microsurgery for
glioma and their respective benefits.
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Classification of glioma
Gliomas are the most common type of primary brain tu-
mour. Their various degrees of malignancy form the basis
of the World Health Organisation (WHO) grading system:
pilocytic astrocytoma is the most benign form of glioma
(WHO Grade I), followed by a heterogeneous group of
so-called “low-grade gliomas” (WHO Grade II) that com-
prises oligodendroglioma, astrocytoma and oligoastrocyt-
oma. Anaplastic glioma (WHO Grade III) is a malignant
and aggressive form of glioma but lacks the malignant
characteristics of the glioblastoma (WHO IV), the most ag-
gressive and most common glioma.
What to do when a glioma is
detected?
Many gliomas become symptomatic with either seizures or
focal neurological deficits and are subsequently detected
via MRI. Although MRI can predict a glioma with high ac-
curacy, in most cases a definite diagnosis must be obtained
by means of histological analysis.
Treatment options depend on the type of glioma, and
patient-specific factors such as location and size of the
glioma, patient age, symptoms and neurological status. In
addition, three molecular markers – 1p/19q co-deletion,
O6-methylguanine methyltransferase (MGMT) promoter
methylation and isocitrate dehydrogenase (IDH) 1/2 muta-
tions – are known to have important diagnostic, prognostic
and predictive (for treatment efficacy) roles in glioma treat-
ment (for reviews see Tabatabai et al. 2010 [1] and Leu et
al. [2]). Treatment may include surgery, radiation therapy
and/or chemotherapy. The role of surgery has been debated
for decades, as sceptics questioned the rationale of surgery
for such an infiltrative disease. However, modern
guidelines recommend primary surgical removal for all
types of gliomas provided that neurological function is pre-
served and the tumour appears locally circumscribed on
magnetic resonance imaging (MRI).
Surgery for low-grade glioma: recent
findings
In order to evaluate the significance of different extents of
resections (EOR) in low-grade glioma, we performed a lit-
erature review of studies reporting survival after surgery
for low-grade glioma over the last 10 years. Three of these
studies included volumetric assessment of the EOR (table
1).
The largest of these studies in patients with low-grade glio-
mas, performed by Capelle et al. [5], showed a strong im-
pact of the EOR on survival, especially when a radiolo-
gical complete resection was obtained [5], and an impact
of the preoperative tumour volume (which invariably cor-
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relates with the EOR) [6]. Although non-controlled series
have a potential selection bias, similar results were found
in a recent study with an unusual geographic and medical
constellation that essentially eliminated the selection bias:
two hospitals in Norway, each taking exclusive care of a
large, stable population, followed different strategies for
patients with low-grade glioma [7]. One of the hospitals
favoured a biopsy followed by a “wait-and-see” strategy,
delaying further therapy until malignant progression while
the other hospital preferred to perform maximal safe re-
section whenever possible. Outcome comparison between
the two hospitals revealed that patients of the surgery-
preferring hospital had a significantly better survival rate,
suggesting that a proactive and aggressive treatment plan
improves survival of low-grade glioma patients (fig. 1).
Moreover, the rate of malignant transformation was twice
as high in the “wait-and-see” cohort [7]. Taken together,
these findings support a proactive and radical surgical ap-
proach for low-grade gliomas rather than a “wait-and-see”
strategy.
A recent Cochrane review emphasised the lack of random-
ised clinical trials or prospective controlled clinical tri-
als on which to base clinical decisions regarding surgery,
underscoring the need for further, preferably randomised,
trials. The review recommended that physicians approach
each case individually and weigh the risks and benefits of
an intervention [8]. Surgical possibilities and potential risks
should thus be explored soon after radiological diagnosis
and certainly before additional tumour growth increases the
risks of malignant transformation.
Figure 1
Patient survival according to hospital treatment strategy.
Patients treated at a hospital that favoured a pro-active strategy
with early radical resection for low-grade glioma had an improved
survival time compared with patients treated in a hospital that
followed a “wait-and-see” strategy after biopsy [7].
After surgery, low-grade gliomas should be observed by
serial MRIs to detect recurrence and progression and may
additionally be treated with adjuvant chemotherapy (te-
mozolomide) or radiotherapy. An individual patient’s pro-
gnosis depends on a variety of factors. Smaller tumour size,
the absence of neurological deficits at diagnosis and oli-
godendroglial histology have a positive influence on over-
all survival (for a web-based calculator of prognosis see
www.eortc.be/tools/lggcalculator) [6]. Molecular markers
are thought to be more accurate than histology for predict-
ing survival; the combination of IDHmut, MGMTmet and
1p/19q co-deletion is associated with the longest survival
[2].
Surgery for glioblastoma: recent
findings
For glioblastoma the impact of surgery on progression-free
survival and overall survival has also been debated for dec-
ades. The lack of adequate assessment of the extent of re-
section and thus of the success of surgery prior to routine
post-operative MRI and volumetric analysis may have con-
tributed to somewhat contradictory results, with institution-
al series arguing both for and against a survival benefit of
resection (for review see Sanai 2012 [9]).
A clearer picture results when the selection of publications
is limited to those that provided volumetric assessment of
the surgical result based on early post-operative imaging.
Three institutional series demonstrated a significant over-
all survival benefit for radical resection of contrast-enhan-
cing tumour as compared to subtotal resection [10–12], and
a fourth series showed a non-significant trend towards im-
proved survival [13].
Moreover, post-hoc analysis of a randomised controlled tri-
al of a surgical adjunct (5–ALA-fluorescence, see below)
revealed a significant survival benefit of almost 5 months
for gross total resection compared to subtotal resection
(16.7 vs 11.8 months; evidence level 2) [14, 15]. This dif-
ference in survival time may be due to an increased effic-
acy of adjuvant treatment after radical resection of the tu-
mour’s solid portion (for review see [16]). A recent report
on advanced modelling found a continuous and exponen-
tial relationship between the extent of resection and surviv-
al, which supports the concept of maximal safe resection of
contrast enhancing tumour [17]. To what extent the benefit
of resection is influenced by the current recommended use
of adjuvant concomitant radio-chemotherapy remains to be
determined.
Table 1: Volumetrically assessed EOR in low grade gliomas and its influence on survival.
Author Number of patients Extent of resection* 5-year survival Multivariate p-value
Claus et al. (2005) [3] 156 100%
<100%
98.2%
92.0%
<0.05
Smith et al. (2008) [4] 216 >90%
<90%
97%
76%
<0.001
Capelle et al. (2013) [5] 1,091 100%
<100%
100%
77%
0.0199
*Assessed as the resection percentage of T2, FLAIR and T2/FLAIR signal abnormality on MRI in the reports of Claus et al, Smith et al. and Capelle et al.
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Detecting tumour tissue: how to
improve the extent of resection?
In the past, a complete resection of enhancing tumour
(CRET) was achieved only in a small minority of glioma
surgeries, presumably due to the difficulty of discerning
tumour tissue from the surrounding brain tissue during
surgery (for high-grade tumours see [18], for low-grade
glioma see [19]). In light of the increasingly convincing
evidence of the benefit of CRET for survival, new tech-
nologies were investigated and implemented for improving
tumour detection. Neuronavigation allows correlation of
any intra-operative point with the preoperative MRI, and
has become standard-of-care at most neurosurgical centres
for intra-operative spatial orientation [20–22] (fig. 2). The
main limitation of neuronavigation is its stepwise loss of
accuracy during surgery [23], which is a source of concern
in the crucial final stages of resection. Despite the use of
neuronavigation the rates of CRET in resectable tumours
are disappointingly low both in low-grade and high-grade
gliomas, and range from 20% to 60%. High-grade glioma
tissue may be detected thanks to the tumour cells’ altered
metabolism: the orally administered drug 5-aminolevulinic
acid (5–ALA) leads to fluorescence of tumour cells during
surgery, allowing identification and resection of tissue that
is otherwise indistinguishable from brain tissue (fig. 3).
Figure 2
Neuronavigation allows correlation of any intra-operative point with
the pre-operative MRI.
Intraoperative neuronavigation facilitates spatial orientation during
surgery at the crucial interface between a low-grade glioma (hyper-
intense), the primary motor cortex (red) and the corticospinal tract
(blue).
Figure 3
The oral prodrug 5-ALA identifies tumour tissue in surgery for
glioblastoma.
Top left: intraoperative view during tumour resection. Top right:
surgical site after removal of all tumour tissue as seen in white light
microscopy. Bottom left: upon switching to microscopic blue light a
small patch of remaining tumour tissue can be seen thanks to
5-ALA fluorescence (arrow). Bottom right: surgical site after
removal of all fluorescent tumour.
The use of 5–ALA significantly increases the rate of suc-
cessful CRET [14], and is thus routinely applied in
neurosurgical centres. In addition, a randomised controlled
trial showed that use of an intraoperative MRI (iMRI) in-
creases the rate of complete resections [24], a result that
can also be obtained using early re-do surgeries for patients
whose post-operative MRI reveals a tumour remnant [25].
These various methods are not mutually exclusive; they
can be used simultaneously and are thus complementary.
The rates of successful complete resection of resectable
tumours improve to 96.2% using a combination of these
techniques, as shown by our group in a consecutive cohort
of patients (the remaining 3.8% of patients had permanent
neurological deficits) [26].
Protecting brain function while
increasing resection: localising
functional tissues to increase safety
Oncological benefits derived from extensive resections
need to be balanced against the risks of neurological de-
ficits. The ability of the above-mentioned technologies to
detect tumour tissue may lead to resections deep into in-
filtrated brain tissue, potentially endangering neurological
function. Stummer et al. showed that 5–ALA guided re-
sections carry a higher risk of post-operative neurological
deterioration than conventional resections (26% vs 15%,
respectively), even though the difference vanished within
weeks [27]. Just as tumour tissue is often indiscernible
from normal brain tissue, functionally critical tissues are
indistinguishable from tissues with less clinically relevant
functions.
Thus, knowing when to stop a resection due to proximity to
areas of crucial neurological functions is of obvious and ut-
most importance. Detailed knowledge of the normal brain
anatomy and distribution of function is not sufficient dur-
ing glioma resection. Interindividual variability and func-
tional relocation (i.e., plasticity) induced by the presence
of an infiltrating tumour [28] requires an exact functional
brain map at the site of surgery in order to spare areas in-
volved in crucial (so-called eloquent) functions. Preoper-
ative localisation of function, either with functional MRI
(fMRI) or navigated transcranial magnetic stimulation
(nTMS), provides an approximate map [29, 30]. Further-
more, intra-operative direct cortical and subcortical elec-
trical stimulation (DCS) for functional analysis of the tis-
sue in the tumour’s infiltration zone is required for accurate
identification of areas that need to be spared in order to
Figure 4
Speech mapping during awake craniotomy.
Left: the patient correctly names items during electrical stimulation
of non-eloquent areas and tumour tissue. Right: speech anomalies
during stimulation reveal eloquent areas (brown) that need to be
spared to avoid postoperative speech deficits.
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retain the patient’s functional integrity [31, 32]. Motor
evoked potentials (MEP) provide real-time information on
the integrity of the primary motor cortex and the cor-
ticospinal tract [33]. Direct cortical mapping (fig. 4) and
phase reversal identify the primary motor and sensory cor-
tices. Subcortical mapping can estimate the distance to the
pyramidal tract, acting as guidance close to functionally
critical areas [34]. When integrated into the existing sur-
gical tools, continuous and dynamic mapping enables more
extensive resection while simultaneously protecting motor
function (fig. 5) [35]. Using these techniques and a detailed
electrophysiological “Bern-concept”, our group achieved
complete motor function protection in 96% of patients with
high-risk motor eloquent tumours (fig. 6) [36]. Further-
A
B
C
more, localisation of cortical and subcortical regions relev-
ant to language function is essential for speech preserva-
tion during resection of gliomas in proximity to presumed
speech areas [31] and requires the patient to be awake dur-
ing the brain mapping part of surgery (fig. 7). Similarly,
intra-operative mapping of visual functions may contribute
to increased resections while avoiding tissue essential for
vision within the temporal and occipital lobes [37].
Presumed eloquence as a modifiable
risk factor for decreased survival
Intraoperative DCS increases the extent of resection by cla-
rifying whether an area preoperatively presumed to be elo-
quent actually is eloquent, and thus extends the resection
right up to the boundary of functional tissue. This concept
D
E
Figure 5
Use of the continuous dynamic mapping device. The continuous
dynamic mapping device is used once the surgeon approaches the
CST (A). Resection is continued with an initial stimulation intensity
of 10–15 mA (corresponding to a distance of 10–15 mm from the
CST). The instant an MEP is elicited (B), the surgeon is alerted by
the change of the high-pitch negative control sound to a low-pitch
alert sound. The stimulation intensity is then reduced by 2 mA, and
the resection is continued at sites negative for the set current (C),
until again the acoustic switch from the negative control to the alert
sound warns the surgeon that the MT has been reached (D). This
stepwise approach is continued until a minimal threshold is reached
(E). Pink indicates tumor tissue, blue indicates CST fibres, green
indicates a region of active resection, and red indicates that an alert
sound has occurred. Copyright Andreas Raabe. Published with
permission.
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of presumed eloquence as a modifiable risk factor predict-
ive of decreased survival time due to subtotal resection
represents a significant improvement in neurological and
oncological risk management. Removing a brain tumour
proximal to an eloquent area without mapping and mon-
itoring requires that a considerable safety margin is main-
tained to spare areas of presumed function, and thereby
forfeits the oncological benefit of maximum resection. A
comparative study between two series with and without
DCS functional mapping led not only to an increase of total
resections (from 6% to 25%), but also to a decrease of neur-
ological deficits (from 17% to 6.5%) [19]. Thus, although
DCS was initially expected to reduce the extent of resec-
tion through identification of unresectable areas, it actually
increased the extent of resection in both low-grade glioma
and glioblastoma [19, 26, 38].
Any benefit for resection beyond the
outer rim of radiological boundaries?
The obvious benefits of extensive, yet tailored and accurate
glioma resections are encouraging, but there is room for
further improvement. Current resection thresholds are in-
variably based on radiologically perceived boundaries
(fluid-attenuated inversion recovery [FLAIR] MRI for low-
grade glioma and gadolinium enhanced T1 MRI for glio-
blastoma), despite our knowledge that the tumour infiltra-
tion goes well beyond these thresholds. Several strategies
Figure 6
Example of a surgery for a lesion adjacent to eloquent tissue lesion.
Left: Preoperative imaging reveals a glioma within the primary
motor cortex. Middle: intraoperative continuous motor mapping
guides surgery in proximity to the corticospinal tract. Right:
postoperative imaging depicts gross total resection.
Figure 7
Left: Overview of cortical mapping for motor function.
Top right: Intraoperative cortical mapping detects no motor function
at sites labeled 1–7.
Bottom right: Motor function of the hand is detected and spared
during surgery at site labeled 8 (further motor function sites
detected and spared at sites 9–15).
aim to increase the oncological benefit of surgery by reach-
ing resection thresholds not visible on MRI. Confocal mi-
croscopes can be used to identify infiltrating low-grade
glioma cells, pushing the resection border into the infilt-
ration zone [39]. Also, supra-total resections of low-grade
gliomas are sporadically attempted in non-eloquent areas to
improve oncological outcome [40]. 5–ALA, known for its
ability to facilitate CRET in high grade gliomas, may lead
to resections beyond the margins of gadolinium MRI due to
its higher sensitivity for tumour [41]. A preliminary study
indicated that extending resection beyond gadolinium and
up to the surgical threshold of 5–ALA complete resection
provides a survival benefit for patients with glioblastoma
[42].
Is there a role for surgery in recurrent
glioma?
The recurrence of glioblastoma after initial surgery and ad-
juvant treatment poses a therapeutic challenge. Evidence
for a survival benefit of a second surgery for glioblastoma
recurrence is scarce [43] and comes from single centre
series in which longer survivals observed in patients with
repeated surgeries may have resulted from selection bias,
rather than treatment. Higher level evidence is required be-
fore re-operation of recurrent glioblastoma can be recom-
mended as standard treatment for defined patient and tu-
mour criteria. Interestingly, many low-grade gliomas are
resectable during the second surgery at sites where func-
tionality prevented tumour resection during the initial sur-
gery [44]. This remarkable finding demonstrates the plas-
ticity of the brain and highlights the importance of brain
mapping to achieve a maximal but safe resection.
Conclusion
Recent reports confirmed the survival benefit derived from
surgery for both low and high grade gliomas. Use of tech-
nical adjuncts such as 5–ALA fluorescence and iMRI for
identification of tumour remnants help to increase the ex-
tent of resection. Intraoperative identification of function
further increases the extent of resection by clarifying
whether an area preoperatively presumed to be eloquent ac-
tually is eloquent, and thus extends the resection right up to
the boundaries of functional tissue while avoiding destruc-
tion of functional tissue. Thus, the devoted and combined
use of the different surgical adjuncts contributes to the goal
of maximum safe resection.
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Figures (large format)
Figure 1
Patient survival according to hospital treatment strategy.
Patients treated at a hospital that favoured a pro-active strategy with early radical resection for low-grade glioma had an improved survival time
compared with patients treated in a hospital that followed a “wait-and-see” strategy after biopsy [4].
Figure 2
Neuronavigation allows correlation of any intra-operative point with the pre-operative MRI.
Intraoperative neuronavigation facilitates spatial orientation during surgery at the crucial interface between a low-grade glioma (hyper-intense),
the primary motor cortex (red) and the corticospinal tract (blue).
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Figure 3
The oral prodrug 5-ALA identifies tumour tissue in surgery for glioblastoma.
Top left: intraoperative view during tumour resection. Top right: surgical site after removal of all tumour tissue as seen in white light microscopy.
Bottom left: upon switching to microscopic blue light a small patch of remaining tumour tissue can be seen thanks to 5-ALA fluorescence
(arrow). Bottom right: surgical site after removal of all fluorescent tumour.
Figure 4
Speech mapping during awake craniotomy.
Left: the patient correctly names items during electrical stimulation of non-eloquent areas and tumour tissue. Right: speech anomalies during
stimulation reveal eloquent areas (brown) that need to be spared to avoid postoperative speech deficits.
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Figure 5
Use of the continuous dynamic mapping device. The continuous dynamic mapping device is used once the surgeon approaches the CST (A).
Resection is continued with an initial stimulation intensity of 10–15 mA (corresponding to a distance of 10–15 mm from the CST). The instant an
MEP is elicited (B), the surgeon is alerted by the change of the high-pitch negative control sound to a low-pitch alert sound. The stimulation
intensity is then reduced by 2 mA, and the resection is continued at sites negative for the set current (C), until again the acoustic switch from the
negative control to the alert sound warns the surgeon that the MT has been reached (D). This stepwise approach is continued until a minimal
threshold is reached (E). Pink indicates tumor tissue, blue indicates CST fibres, green indicates a region of active resection, and red indicates
that an alert sound has occurred. Copyright Andreas Raabe. Published with permission.
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Figure 6
Example of a surgery for a lesion adjacent to eloquent tissue lesion.
Left: Preoperative imaging reveals a glioma within the primary motor cortex. Middle: intraoperative continuous motor mapping guides surgery in
proximity to the corticospinal tract. Right: postoperative imaging depicts gross total resection.
Figure 7
Left: Overview of cortical mapping for motor function.
Top right: Intraoperative cortical mapping detects no motor function at sites labeled 1–7.
Bottom right: Motor function of the hand is detected and spared during surgery at site labeled 8 (further motor function sites detected and spared
at sites 9–15).
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